Latest in Europe & UK Biotech

biospace.com
297 words

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

Baseline Prognostic Imbalance Provides Important Context for ITT Results Early DFS Separation and Immune Findings Support Further Evaluation About the AMPLIFY-7P Phase 2 Study AMPLIFY-7P Phase 2 is a randomized study evaluating camupepimut versus observation in patients with mutant KRAS-driven pancreatic ductal…

Europe & UK Biotech

Biotech in Europe and Britain: companies, funding, clusters such as Cambridge, Oxford, Basel and Copenhagen, and the policy affecting them.

  • 61 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

  • +21 more